Dr Fangli Chen > Proskauer Rose LLP > Boston, United States > Lawyer Profile

Proskauer Rose LLP
ONE INTERNATIONAL PLACE, 14TH FLOOR
BOSTON, MA 02110-2600
MASSACHUSETTS
United States
Fangli Chen photo

Work Department

Litigation

Position

Dr. Fangli Chen is a partner in Proskauer’s Litigation Department and chair of the Life Sciences Patent Practice. She represents all types of companies in the biotech and pharmaceutical industries, and has deep scientific expertise and a strong business sense. Fangli effectively identifies and transforms technological developments into valuable intellectual property assets for her clients and specializes in the strategic development of complex IP portfolios for companies that align with their business goals.

Fangli’s practice also focuses on post-grant review before the USPTO, oppositions, pre-litigation and litigation strategy, due diligence investigations, freedom-to-operate, non-infringement and invalidity analysis, licensing and other IP matters in connection with commercial transactions. She handles a variety of technology areas including biochemistry, molecular and cell biology, immunotherapy, enzyme replacement therapy, nucleic acid based technologies including messenger RNA therapy, gene therapy, gene editing, antisense and oligonucleotides based therapies, vaccines, bioinformatics, and small molecule compound drugs.

Fangli also has a wealth of experience in the following areas:

Post-grant challenges: representing clients in inter partes review interference and various foreign opposition proceedings.

Technology transactions & licensing: advising clients on matters relating to technology or material transfer, licensing and research collaborations.

Investment or acquisition counsel: assisting investors in assessing the technology and intellectual property assets and risks for potential target investments and counseling companies on intellectual property matters in connection with public offering or acquisition.

Lawyer Rankings

United States > Healthcare > Life sciences

Proskauer Rose LLP‘s life sciences practice is particularly adept at handling multi-faceted patent disputes concerning biologics, medical devices and pharmaceutical developments, and 2023 saw the team expand with the arrivals of Erik Milch in Washington DC and Joseph Drayton in New York from Cooley LLP in July and October respectively, while Morrison Foerster‘s Grant Esposito and David Fioccola also joined the New York office in October. The team is led by Boston’s ‘excellent patent lawyer’ Fangli Chen, whose litigious experience encompasses immunotherapy, gene therapy and editing and vaccines, managing partner and transactions specialist Daryn Grossman in New York, and Siegmund Gutman, who represents clients in patent disputes concerning biologics and in Hatch-Waxman disputes out of Los Angeles.